- Diabetes Treatment Becomes Affordable
- Patent Expiry Opens Market
- Rising Dual Health Burden
Article Today, Hyderabad:
India continues to face a growing burden of diabetes alongside increasing obesity levels. Together, these conditions raise the risk of heart disease and other chronic illnesses. Therefore, medicines that address both blood sugar control and weight reduction have drawn sharp attention from patients and policymakers alike.
A Critical Patent Expiry
Novo Nordisk developed Ozempic, a drug that gained global prominence for treating type two diabetes and aiding weight loss. However, the expiry of its key patent has now opened the door for generic manufacturers. This shift has cleared the regulatory path for Indian pharmaceutical companies to enter the segment.
Dr Reddy’s Market Entry
Dr Reddy’s Laboratories is preparing to launch a generic version of Ozempic in the domestic market from March. The Hyderabad-based company aims to make the treatment widely accessible. In addition, the move is expected to reduce dependence on costly imports.
Impact on Treatment Costs
Currently, the branded version of Ozempic remains expensive for most Indian patients. Monthly treatment often runs into several thousand rupees. However, the entry of a domestic generic is likely to bring prices down significantly. Industry observers expect intensified competition to benefit patients over time.
Commercial Growth Prospects
The global market for weight loss and diabetes drugs is expanding rapidly. Estimates place its value at several trillion rupees over the coming years. Therefore, Dr Reddy’s sees this launch as a major revenue opportunity. The company may also explore exports to other emerging markets once domestic supply stabilises.
Competitive Pharma Landscape
Dr Reddy’s is not alone in targeting this opportunity. Companies such as Sun Pharma and Zydus Lifesciences are also developing similar products. Meanwhile, Dr Reddy’s is expected to be among the earliest entrants, giving it an initial advantage.
Public Health Significance
India has more than 100 million people living with diabetes. Many also struggle with obesity-related complications. Therefore, wider access to effective medication could ease pressure on the healthcare system. Experts note that such drugs may help lower long-term risks linked to cardiovascular disease.
Medical Community Response
Doctors and health specialists have welcomed the move toward domestic production. Until now, limited availability and high prices restricted patient access. With local manufacturing, supply is expected to stabilise. As March approaches, both patients and the pharmaceutical industry are closely watching the rollout.
